Is Gene Therapy for Hypertension Possible?

Hypertension

Volumn 33, Issue 1, 1999, Pages 8-13

  Phillips, M Ian ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSINOGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; VIRUS VECTOR;

ADENOVIRUS; BLOOD PRESSURE REGULATION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC LINKAGE; HUMAN; HYPERTENSION; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROVIRUS; TREATMENT PLANNING; VASOCONSTRICTION; VASODILATATION;

ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; DNA, ANTISENSE; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPERTENSION; OLIGONUCLEOTIDES, ANTISENSE; PROMOTER REGIONS (GENETICS); RATS; RATS, INBRED DAHL; RATS, INBRED SHR; RETROVIRIDAE; TIME FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 0032890904     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.33.1.8     Document Type: Editorial

References (48)

1. Junemaitre X, Soubrier F, Kotelvtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, William RR, Lalouel JM, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
2. Siffert W, Rosskopf D, Siffer G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta 3 subunit variant with hypertension. Nat Genet. 1998;18:45-48.
3. Lifton RP. Molecular genetics of human blood pressure variation. Science. 1996;272:676-680.
4. Watanabe T, Yonemura K, Fujigaki Y, Suzuki T, Motomura E, Sano K, Ikegaya N, Yamamoto T, Kimura M, Hisida A, Kaneko E. Despite low plasma renin ACE inhibitor treatment causes recovery from acute renal failure in a patient with malignant hypertension. Nephrol Dial Transplant. 1998;13:769-772.
5. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey. Hypertension. 1995;25:305-313.
6. Tanimto K, Sugiyama F., Goto Y, Ishida J, Takimoto E, Yagami K. Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypotension. J Biol Chem. 1994;269:31334-31337.
7. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A. 1995;92:2735-2739.
8. Schinke M, Bohm M, Bricca G, Ganten D, Bader M. Permanent inhibition of angiotensinogen synthesis of antisense RNA expression. Hypertension. 1996;27:508-513.
9. Smythies O. A mouse view of hypertension. Hypertension. 1997;30:1318-1324.
10. Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995;26:847-853.
11. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997;30(pt 1):307-313.
12. Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest. 1995;95:1710-1716.
13. Yayama K, Wang C, Chao L, Chao J. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension. 1998;31:1104-1110.
14. Chao J, Zhang JJ, Lin K-F, Cho L. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther. 1998;9:21-31.
15. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept. 1993;49:167-174.
16. Phillips MI, Wielbo D, Gyurko R. Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int. 1994;46:1554-1556.
17. Phillips MI, Gyurko R. Antisense oligonucleotides: new tools for physiology. News Physiol Sci. 1997;12:99-105.
18. Wielbo D, Sernia C, Gyurko R, Phillips MI. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension. 1994;25:314-319.
19. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science. 1993;261:1004-1012.
20. Li B, Hughes JA, Phillips MI. Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurchem Int. 1996;31:393-403.
21. 1 angiotensin receptor mRNA in spontaneously hypertensive rats. Am J Hypertens. 1997;10:56S-62S.
22. Tomita N, Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, Fukamizu A, Murakami K, Kaneda Y, Ogihara T. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension. 1995;26:131-136.
23. Wielbo D, Simon A, Phillips MI, Toffolo S. Inhibition of hypertensin by peripheral administration of antisense oligodeoxynucleotides. Hypertension. 1996;28:147-151.
24. Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension. 1998;31:1166-1170.
25. Galli SM, Varela A, Phillips MI. Lowering of blood pressure and catecholamines in chronic but not in acute 2 kidney-1 clip rats by antisense oligodeoxynucleotide to angiotensin mRNA. Hypertension. 1995;26:557. Abstract.
26. 1 receptor mRNA in brain and blood. Hypertension. 1998;31:1317-1323.
27. Crooke ST. Antisense therapeutics. In: Cuello AC, Collier B, eds. Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990's. Basel, Switzerland: Birkhauser Verlag; 1995.
28. Crystal RG. Transfer of genes to humans: early lesson and obstacles to success. Science. 1995;270:404-410.
29. Leiden JM. Gene therapy: promise, pitfalls and prognosis. N Engl J Med. 1995;333:1204-1207.
30. Iyer SN, Lu D, Katovich M, Raizada MK. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc Natl Acad Sci U S A. 1996;93:9960-9965.
31. Martens JR, Reaves PY, Lu D, Katovich MJ, Berecek KH, Bishop SP, Raizada MK, Gelband CH. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci U S A. 1998;95:2664-2669.
32. Nabel EG, Plautz G, Boyce FN, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 1989;244:1342-1344.
33. Chang MW, Barr E, Setzler J, Jiang Y-Q, Nabel GJ, Nabel EG, Phamacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
34. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science. 1989;244:1344-1346.
35. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointimal formation after arterial injury. Nat Med. 1996;2:293-298.
36. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther. 1996;7:1555-1566.
37. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 1996;2:545-550.
38. Muzyczka N, McLaughin S. Use of adeno-associated virus as a mammalian transduction vector. In: Gluzman Y, Hughes, SH, eds. Current Communications in Molecular Biology: Viral Vectors. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988:39-44.
39. Ponnazhagan S, Nallari ML, Srivastava A. Suppression of human a-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectors. J Exp Med. 1994;179:733-738.
40. Chatterjee S, Johnson PR, Wong KK. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science. 1992;258:1485-1488.
41. Flotte TR, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R. A phase I study of an adeno-associated virus-CTFR gene vector in adult CF patients with mild lung disease. Hum Gene Ther. 1996;7:1145-1159.
42. Phillips MI. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension. 1997;29:177-187.
43. Lebkowski JS, McNally MM, Okarma TB, Lerch B. Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types. Mol Cell Biol. 1988;8:3988-3996.
44. Mohuczy D, Wang S, Klein RL, Meyers C, Hughes JA, Phillips MI, King MA, Muzyczka N, Meyer EM. Pharmacokinetic evaluation of AAV-mediated gene transfer into the brain. Soc Neurosci. 1998;24:1287. Abstract.
45. Wu P, Phillips MI, Bui J, Terilliger EF. Adeno-associated viral vector mediated transgene integration in nondividing cells. J Virol. 1998;72:5919-5926.
46. 1-R mRNA antisense. Hypertension. 1997;29:374-380.
47. Suzuki S, Pilowsky P, Minson J, Arnolda L, Llewellyn-Smith IJ, Chalmers J. c-fos antisense in rostral ventral medulla reduces arterial blood pressure. Am J Physiol. 1994;266(pt 2):R1418-R1422.
48. Suzuki S, Pilowsky P, Minson J, Arnolda L, Llewelly-Smith IJ, Chalmers J. Antisense to thyrotropin releasing hormone receptor reduces arterial blood pressure in spontaneously hypertensive rats. Circ Res. 1995;77:679-683.